Archives
-
Anagliptin (SK-0403): DPP-4 and Vascular Mechanisms
2026-09-17
Anagliptin (SK-0403) is an orally active DPP-4 inhibitor with a reported IC50 of 3.8 nM. In rabbit aortic rings, the compound produced vasorelaxation associated with Kv channel and SERCA pump activity, while classic cyclic-nucleotide pathways and the endothelium were not required.
-
Diuron: From Photosynthesis to Renal Toxicology
2026-09-16
Diuron is both a mechanistically defined photosynthesis inhibitor and a valuable model for environmental toxicology. This article presents an assay-translation framework linking its plant target to emerging evidence on JAK2/STAT1-associated renal injury.
-
Dehydroepiandrosterone (DHEA) Experimental Workflows
2026-09-16
Build reproducible DHEA workflows for PCOS models, granulosa-cell apoptosis, macrophage-conditioned media, and neuroprotection studies. This guide connects dose selection and vehicle control with practical assays for granulosa cell proliferation, hippocampal neuron protection, and apoptosis inhibition.
-
Gemini Quaternary Ammonium Compounds: Study Insights
2026-09-15
The reference study synthesizes 16 novel octenidine-derived gemini quaternary ammonium compounds and evaluates their antibacterial, antibiofilm, antifungal, antiviral, and cytotoxicity profiles. Compounds 1 and 12 were especially notable for fungal selectivity or broad-spectrum activity, while the structure–activity analysis illustrates how polarity and molecular design can improve the performance of antiseptic research compounds.
-
Tioconazole (B2051) in Reproducible Fungal Assays
2026-09-15
This scenario-driven guide explains how Tioconazole, SKU B2051, can improve solvent control, dose preparation, and interpretation in fungal viability and cytotoxicity workflows. It links product specifications with practical assay design while distinguishing validated antifungal evidence from exploratory cross-domain applications.
-
Iron Stress Reprograms Enterocyte Metabolism
2026-09-14
Navazesh and Ji used IPEC-J2 enterocytes to show that both iron deficiency and iron excess produce distinct metabolic and transcriptional programs. The study links iron deficiency to impaired proliferation, altered central carbon metabolism, and inflammatory signaling, while iron excess favors cholesterol synthesis and lowers alpha-tocopherol, with partial recovery after iron repletion.
-
BRD4–RAC1 Co-Targeting in Breast Cancer
2026-09-14
The reference study identifies combined BRD4 and RAC1 inhibition as a subtype-aware strategy that suppresses breast cancer growth, stemness, migration, and tumorigenesis. Its mechanistic contribution is the linkage of BRD4–RAC1 blockade to disruption of the c-MYC–G9a–FTH1 axis and downregulation of HDAC1, providing a useful framework for interpreting combination strategies in cancer epigenetics.
-
Tioconazole: Antifungal Mechanism and Research Use
2026-09-13
Tioconazole is an antifungal medication that disrupts fungal ergosterol production through inhibition of fungal cytochrome P450 activity. Its defined identity, solubility specifications, storage guidance, and research-only status support controlled in vitro antifungal assays and fungal infection models.
-
Nintedanib (BIBF 1120) Assay Guide
2026-09-12
A scenario-driven guide to using Nintedanib (BIBF 1120), SKU A8252, in viability, apoptosis, proliferation, and cytotoxicity workflows. It connects documented kinase potency, formulation, storage, and ATRX-relevant literature to practical experimental decisions.
-
Amyloid Beta-Peptide (1-40): Applied Workflows
2026-09-11
Build reproducible amyloid fibril formation studies, membrane-interaction assays, and cell-based neurotoxicity mechanism investigations with a defined human Aβ40 model. The workflow combines controlled peptide handling with surface-sensitive spectroscopy to distinguish bulk aggregation from membrane-associated events.
-
DiscoveryProbe™ Immunology/Inflammation Compound Library
2026-09-11
The DiscoveryProbe Immunology/Inflammation Compound Library enables decision-focused immunomodulator screening across innate and adaptive immune phenotypes. This guide explains how to translate multiplex PBMC responses into target validation, pathway-level hypotheses, and better follow-up experiments.
-
Primidone, RIPK1, and ALS Biomarkers
2026-09-10
A 2023 study connected pharmacological RIPK1 inhibition with measurable changes in peripheral biomarkers in amyotrophic lateral sclerosis (ALS). Using SOD1G93A mice and a 24-week patient study, the authors found that Primidone reduced serum RIPK1 and IL-8, supporting a translational biomarker strategy while leaving questions about target engagement, specificity, and clinical efficacy open.
-
Palomid 529 in ESCC Research Workflows
2026-09-10
Palomid 529 (P529) provides a practical way to interrogate dual mTORC1 and mTORC2 signaling in esophageal squamous cell carcinoma models. This guide connects pathway validation with cisplatin resistance, metastasis, tumor angiogenesis inhibition, and radiotherapy enhancement while emphasizing reproducible dosing and troubleshooting.
-
SAG for Hedgehog Pathway Assays and Models
2026-09-09
SAG provides a controllable Smoothened receptor agonist signal for reporter assays, mechanistic inhibitor studies, neurobiology, developmental models, and translational disease research. This guide combines product-specific handling data with an assay strategy that distinguishes Smoothened-level effects from downstream GLI activity.
-
Rotavirus Suppression of Nrf2 Redox Defense
2026-09-09
The reference study shows that rotavirus infection produces a biphasic Nrf2 response: an early, redox-sensitive induction followed by pronounced loss of Nrf2 and its antioxidant transcriptional program. Its key contribution is linking late Nrf2 depletion to proteasome-sensitive, K48-linked ubiquitination rather than simply attributing the change to sustained oxidative stress.